Philips and NYU Langone's $115M, 8-year partnership for innovative patient care

In a groundbreaking collaboration, Philips and NYU Langone Health have unveiled a dynamic 8-year strategic partnership with a valuation of up to $115 million. This ambitious venture is poised to revolutionise patient care by leveraging cutting-edge innovation.

The primary objective of this partnership is to pioneer the development of technologies that empower NYU Langone clinicians to engage in real-time collaboration, seamlessly share critical patient data, and craft personalised care plans. The technological advancements will not only streamline workflows but also hold the promise of reducing costs and elevating overall healthcare outcomes.

Central to this collaboration is NYU Langone's adoption of a suite of advanced solutions from Philips. The adoption includes the implementation of Philips' IntelliSite Pathology solution, enterprise informatics, and state-of-the-art AI-enabled diagnostic imaging technologies such as the Philips Lumify Handheld Ultrasound. Additionally, NYU Langone will integrate the Philips Patient Information Center iX and the Philips Capsule Medical Device Information Platform (MDIP) into its operations. These solutions are strategically designed to simplify workflows and unlock the transformative potential of data.

One notable inclusion in the partnership is the deployment of Philips Capsule MDIP under a predictable EMaaS (Enterprise Management as a Service) subscription model. This innovative approach ensures seamless integration across the healthcare network, promoting a cohesive and unified healthcare ecosystem.

The collaborative strategy is centred on an integrated approach aimed at enhancing the overall patient experience. By enabling faster diagnosis, expediting treatment processes, and ultimately improving outcomes, the partnership aligns seamlessly with NYU Langone's unwavering commitment to innovation and precision medicine.